Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05977205
Other study ID # NL73778.058.20
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2, 2020
Est. completion date July 10, 2020

Study information

Verified date August 2023
Source Leiden University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Diabetes mellitus is a chronic disease characterized by the inability of the body to maintain normoglycemia. Treatment of diabetes relies mostly on diabetes self-management, requiring a large investment of time and energy on a daily basis. Psychological wellbeing, behavioral patterns and social context play a major role in diabetes self-management and glycemic control. Social isolation behavior (self-quarantining) may impact glycemic control by influencing daily routines, therapy adherence, physical activity, and self-measurement and eating behaviors. Therefore, a period of nationwide self-quarantine, such as during the lockdown issued during the COVID-19 outbreak in the Netherlands, may have a large effect on glycemic control in patients with diabetes. In this observational cross sectional study, we aim to assess the impact of long-term self-quarantine on glycemic control, diabetes self-management and distress in patients with type 1 and type 2 diabetes mellitus. A specific subgroup of patients with T1D are those with complicated diabetes who have received a pancreas or islet transplantation and use immunosuppression, having multiple risk factors for severe COVID-19. The impact of lockdown strategies on mental and physical health is expectedly even greater in patients at even higher risk for severe COVID-19. We therefore additionally investigated differences in behavioral, mental and physical implications of a nationwide lockdown on patients with type 1 diabetes with and without islet or pancreas transplantation. Measurements will be performed during the lockdown period. Patients will be asked to perform a fingerprick HbA1c measurement once, sent back to the LUMC by mail. Data from continuous or flash glucose monitoring devices will be collected according to standard clinical practice. Furthermore, patients will be asked to fill out an online questionnaire once on diabetes self-management behavior, well-being and distress, along with questions about health status, level of education, medication use, employment, social situation and the impact of self-quarantine on daily routines. In this questionnaire, we ask patients to compare certain aspects of their life (e.g. anxiety, stress, weight, physical activity, glycemic control) at the time of the lockdown to before the lockdown. Data on demographics, type of diabetes, weight, BMI and HbA1c prior to the COVID-19 outbreak will be derived from the patient's electronic health file.


Recruitment information / eligibility

Status Completed
Enrollment 492
Est. completion date July 10, 2020
Est. primary completion date July 10, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Diagnosed with type 1 or type 2 diabetes - Ability to perform fingerpricks - Sufficient comprehension of the Dutch language - Ability to fill out online questionnaires Exclusion Criteria: - Pregnancy - Newly diagnosed malignancy, with the exclusion of non-melanoma skin cancer, in the previous 6 months - Chemotherapy or immunotherapy for malignancy - Admission to hospital or rehabilitation center

Study Design


Intervention

Other:
No interventions, observational study
Not applicable, no interventions, observational study

Locations

Country Name City State
Netherlands Leiden University Medical Center Leiden Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemic control HbA1c (mmol/mol Hb) HbA1c measurement during lockdown (8 - 11 weeks after the start of the lockdown (March 15th 2020)) compared to last measurement before lockdown (last known measurement before March 15th 2020)
Secondary Glycemic control Continuous Glucose Measurement parameters (time in range, time above range, time below range) 2 week period during lockdown compared to 2 week period before lockdown
Secondary Stress Perceived Stress Scale (PSS) + self-reported change in stress during lockdown compared to before lockdown PSS During lockdown + self-comparison change to before lockdown (questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Anxiety Self-reported change in anxiety during lockdown compared to before lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Weight Self-reported weight change during lockdown compared to before lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Physical activity Self-reported change in physical activity during lockdown compared to before lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Glycemic control and insulin requirements Self-reported change in difficulty with glycemic control and insulin requirements during lockdown compared to before lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Social isolation behaviour Self-reported social isolation behaviour during lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
Secondary Fear of COVID-19 infection Fear of contracting COVID-19, scored using a Visual Analogue Scale (1-10), during lockdown Questionnaire filled in between 8 - 11 weeks after the start of the lockdown (March 15th 2020))
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A